Search

Displaying results 8341 - 8350 of 10000 in total
  1. Drug

    Vanucizumab

    go.drugbank.com/drugs/DB12317
    Investigational

    Vanucizumab has been used in trials studying the treatment of ColoRectal Cancer and Advanced/Metastatic Solid Tumors.

  2. Drug

    Somavaratan

    go.drugbank.com/drugs/DB12421
    Investigational

    Somavaratan has been used in trials studying the treatment of Growth Disorders and Adult Growth Hormone Deficiency.

  3. Drug

    Verdiperstat

    go.drugbank.com/drugs/DB12440
    Investigational

    Verdiperstat has been used in trials studying the basic science and treatment of Multiple System Atrophy (MSA).

  4. Drug

    Tovetumab

    go.drugbank.com/drugs/DB12609
    Investigational

    Tovetumab has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Advanced Solid Malignancies.

  5. Drug

    BMS-188797

    go.drugbank.com/drugs/DB12619
    Investigational

    BMS-188797 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.

  6. Drug

    Ibipinabant

    go.drugbank.com/drugs/DB12649
    Investigational

    Ibipinabant has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes.

  7. Drug

    Omipalisib

    go.drugbank.com/drugs/DB12703
    Investigational

    Omipalisib has been used in trials studying the treatment of CANCER, Solid Tumours, and Idiopathic Pulmonary Fibrosis.

  8. Drug

    Mitoguazone

    go.drugbank.com/drugs/DB12967
    Investigational

    Mitoguazone has been used in trials studying the treatment of Lymphoma, HIV Infections, and Lymphoma, Non-Hodgkin.

  9. Drug

    Hu-rhEGF-rP64k/Mont

    go.drugbank.com/drugs/DB15781
    Investigational

    Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated

  10. Drug

    Escin

    go.drugbank.com/drugs/DB15907
    Investigational

    prognosis in massive cerebral infarction) and NCT05263167 (aimed at reducing edema after intracerebral hemorrhage). … Sodium aescinate is under investigation in clinical trials for its potential to treat cerebral conditions, including NCT04247659 (studying the relationship between asymmetric vascular sign of cortex and